Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 6/20 | 0.40 |
| ▸ | MAOB | P27338 | 6/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | XBP1 | P17861 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9647298 | 0.85 | MAOA (0.42) | MAOAMAOBTSHRMAPTALDH1A1 | |
| SCHEMBL2540632 | 0.79 | NPC1 (0.50) | TSHRMAPTALDH1A1RAB9ALMNA | |
| SCHEMBL11609342 | 0.79 | MAOA (0.38) | MAOAMAOBMAPTALDH1A1NPSR1 | |
| SCHEMBL1617208 | 0.77 | STAT3 (0.52) | MAPTALDH1A1PTGS2RAB9ALMNA | |
| SCHEMBL15413487 | 0.75 | MAOA (0.44) | MAOAMAOBMAPTNPSR1EGFR | |
| SCHEMBL58239 | 0.74 | MAOA (0.47) | MAOAMAOBTSHRMAPTALDH1A1 | |
| SCHEMBL27516701 | 0.74 | TSHR (0.36) | TSHRALDH1A1NPSR1PTGS2LMNA | |
| SCHEMBL3752087 | 0.73 | MAOA (0.50) | MAOAMAOBMAPTALDH1A1LMNA | |
| SCHEMBL161364 | 0.72 | ALDH1A1 (0.50) | MAOAMAOBTSHRMAPTALDH1A1 | |
| SCHEMBL9330920 | 0.71 | MAOA (0.48) | MAOAMAOBTSHRMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2318361-B1 | SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS | NOVARTIS AG (CH) | 2015-09-23 | — | — | EP | disclosed |
| US-8841291-B2 | Selective hydroxamic acid based MMP-12 and MMP-13 inhibitors | NOVARTIS AG (CH) | 2014-09-23 | — | — | US | disclosed |
| US-20140031399-A1 | SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS | NOVARTIS AG (CH) | 2014-01-30 | — | — | US | disclosed |
| CN-102143942-A | Selective hydroxamic acid based MMP-12 and MMP-13 inhibitors | NOVARTIS AG | 2011-08-03 | — | — | CN | disclosed |
| US-20110112076-A1 | SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS | NOVARTIS AG (CH) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112076-A1 | SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS | MMP13, MMP11, MMP14 | MAOA 114/4885MAOB 227/4885TSHR 3825/4885 |
| US-20140031399-A1 | SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS | MMP13, MMP11, MMP14 | MAOA 110/4885MAOB 217/4885TSHR 3811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.